2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
29
avelumab
21
Nivolumab
20
Ipilimumab
10
Radiotherapy
9
Cyclophosphamide
9
atezolizumab
8
cemiplimab
7
fludarabine
6
Specimen Handling
6
durvalumab
5
aldesleukin
5
Radiation
5
Magnetic Resonance Spectroscopy
5
Interleukin-2
5
Biopsy
5
talimogene laherparepvec
4
ALT-803
4
poly ICLC
3
Radiosurgery
3
Etoposide
3
Cisplatin
3
Carboplatin
3
CTLA-4 Antigen
3
Bevacizumab
3
prednylidene
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
domatinostat
2
deltacortene
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
MAPRE1 protein, human
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled